Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

789 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Noronha V, et al. Among authors: more s. J Clin Oncol. 2020 Jan 10;38(2):124-136. doi: 10.1200/JCO.19.01154. Epub 2019 Aug 14. J Clin Oncol. 2020. PMID: 31411950 Clinical Trial.
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.
Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Patil VM, et al. Among authors: more s. ESMO Open. 2017 Apr 27;2(1):e000168. doi: 10.1136/esmoopen-2017-000168. eCollection 2017. ESMO Open. 2017. PMID: 28761735 Free PMC article.
Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents.
Noronha V, Joshi A, Patil VM, Banavali SD, Gupta S, Parikh PM, Marfatia S, Punatar S, More S, Goud S, Nakti D, Prabhash K. Noronha V, et al. Among authors: more s. Asia Pac J Clin Oncol. 2018 Apr;14(2):e129-e137. doi: 10.1111/ajco.12762. Epub 2017 Aug 28. Asia Pac J Clin Oncol. 2018. PMID: 28849623 Clinical Trial.
Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy.
Noronha V, Patil V, Joshi A, Chougule A, Bhattacharjee A, Kumar R, More S, Goud S, Karpe A, Ramaswamy A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Noronha V, et al. Among authors: more s. Ecancermedicalscience. 2017 Oct 24;11:776. doi: 10.3332/ecancer.2017.776. eCollection 2017. Ecancermedicalscience. 2017. PMID: 29104613 Free PMC article.
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Joshi A, Noronha V, Patil VM, Chougule A, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Joshi A, et al. Among authors: more s. Chemother Res Pract. 2017;2017:8196434. doi: 10.1155/2017/8196434. Epub 2017 Oct 23. Chemother Res Pract. 2017. PMID: 29201462 Free PMC article.
Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
Joshi A, Patil V, Noronha V, Chougule A, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Joshi A, et al. Among authors: more s. Lung India. 2018 Jan-Feb;35(1):27-30. doi: 10.4103/lungindia.lungindia_201_17. Lung India. 2018. PMID: 29319030 Free PMC article.
Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.
Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K. Patil V, et al. Among authors: more s. EClinicalMedicine. 2019 Apr 9;9:19-25. doi: 10.1016/j.eclinm.2019.03.011. eCollection 2019 Mar. EClinicalMedicine. 2019. PMID: 31143878 Free PMC article.
Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer.
Patil V, Joshi A, Noronha V, Agarwala V, Chougule A, Kanan S, Bhattacharjee A, Chandrasekharan A, Pande N, Simha V, Goud S, More S, Kumar R, Mahajan A, Janu A, Purandare N, Prabhash K. Patil V, et al. Among authors: more s. Oncotarget. 2019 Oct 29;10(59):6297-6307. doi: 10.18632/oncotarget.27214. eCollection 2019 Oct 29. Oncotarget. 2019. PMID: 31695838 Free PMC article.
789 results